Accelerating Africa’s Progress in Developing, Testing and Deploying Emerging Health Technologies

By Pauline Soy and Adaudo Anyiam-Osigwe

Panel discussion (From left, Dr Rose Oronje, Director of Public Policy and Knowledge Translation at AFIDEP, Prof. Richard Mukabana, Senior Research and Policy Analyst at AFIDEP, Leka Tingitana, Director, Tanzania Flying Labs, Dr Said Jongo, Consultant Physician and Clinical Epidemiologist at Ifakara Health Institute (IHI), and Dr Collins Mweresa, Senior Lecturer of Medical Entomology and Applied Parasitology atJaramogi Oginga Odinga University of Science and Technology (JOOUST).

The African Union Agenda 2063 recognises that technology is essential to advancing the economic growth of the continent. To this end, the African Union tasked its development agency, AUDA-NEPAD, to create the Africa Union High-level Panel on Emerging Technologies (APET). APET offers expert guidance on technology and development issues. The recommendations from the panel will allow Africa to utilise current and emerging technologies and innovations that have the potential to accelerate socio-economic development.

With regard to health, APET has prioritised several emerging technologies that, if successfully developed, tested and deployed, could improve overall health on the continent. On 8 March 2023, the Platform for Dialogue and Action on Health Technologies in Africa (Health Tech Platform) hosted a parallel session titled “Accelerating Africa’s Progress in the Development, Testing and Deployment of Emerging Health Technologies” at the Africa Health Agenda International Conference (AHAIC), held in Kigali, Rwanda. The session brought together experts to discuss some priority health technologies, including gene drives and monoclonal antibodies for malaria control and the use of drones and microgrids in healthcare. This discussion fed into the overall theme of the conference – “Resilient Health Systems for Africa: Re-envisioning the Future Now”.

Monoclonal antibodies for malaria prevention

The presentation by Dr Said Jongo, Consultant Physician and Clinical Epidemiologist at Ifakara Health Institute, focused on the potential of monoclonal antibodies for malaria prevention. Monoclonal antibodies (mAbs) are lab-manufactured proteins that mimic the function of antibodies, designed to target specific proteins in cells and can block the cell’s function or mark it for destruction.

At the session, Dr Jongo presented the complex process of developing these monoclonal antibodies for malaria prevention, which requires multidisciplinary commitments, and few African countries have the necessary infrastructure and expertise for their development. Dr Jongo recommended establishing research partnerships with international organisations; developing local talent through training programmes; streamlining regulatory policies to promote the development of new drugs and technologies; and establishing facilities for producing and validating biologics. Such targeted efforts to build capacity for biotechnology and drug development in Africa will help in scaling up research and production of monoclonal antibodies for malaria prevention and other diseases that disproportionately affect African populations.

Gene drive mosquitoes for malaria control
Researchers are also exploring the use of gene drives mosquitoes for malaria control and elimination in Africa. Gene drive refers to a technique where an organism is genetically modified to favour the transfer of preferred traits from one generation to the next during sexual reproduction, resulting in the rapid spread of these traits within a few generations. The development of this technology for malaria control is hampered by the limited capacity of African institutions and researchers​; limited priority and investments by African governments​; limited engagement of Africans ​in general; and growing opposition to its development.

In his presentation, Professor Richard Mukabana, Senior Research and Policy Analyst at the African Institute for Development Policy, urged participants to embrace scientific evidence in decision-making, not myths and unfounded statements against gene drive technology. He noted that African leadership is essential in harmonising regulations to enable research and testing of gene drive mosquito technology in Africa, providing further scientific evidence to guide decisions.

Drones in Healthcare 

Tanzania, very early on, embraced drone technology and put in place regulations to support its use in healthcare. As such, organisations such as Tanzania Flying Labs are using drones to deliver medicines, vaccines and patient samples, identifying mosquito breeding grounds; and larviciding habitats mosquitoes are likely to thrive.

Nevertheless, as Leka Tingitana, Director of Tanzania Flying Labs, noted in his presentation, Tanzania and other African countries need better drone regulations and policies to guide the use and mainstreaming of the technology.  Furthermore, countries need to cultivate a culture of innovation through education and capacity-strengthening activities, as well as harmonise cross-border regulations, to allow broad use of this technology.

Solar microgrids for vector-borne disease control

Dr Collins Mweresa, Senior Lecturer of Medical Entomology and Applied Parasitology at Jaramogi Oginga Odinga University of Science and Technology (JOOUST), presented a case study on how microgrids can be successfully deployed for vector-borne disease control. A microgrid is a self-sufficient energy system which relies mainly on renewable energy sources such as wind and solar and can be harnessed to provide power to a discrete locale, for instance, a hospital.

In his presentation, Dr Mweresa narrated how solar-powered, odour-baited traps (OBTs) were used in the mass trapping of mosquitoes on Rusinga Island in western Kenya. The research team found out that the proportion of persons with malaria was 30% lower among those living in houses with OBTs compared to counterparts who lived in houses without the OBTs. Therefore, modifying and adapting the technology to local situations and upscaling to control vector-borne diseases in Africa can contribute to eliminating malaria in Africa.

Feedback from the session

The presentations and discussion at the AHAIC session revealed that while emerging health technologies could complement current health intervention strategies and ensure positive health outcomes on the continent, there are several impediments which may undermine progress. Key among these impediments is limited or no regulations in fostering innovation and best practices to serve the needs of Africa’s populations. Nevertheless, the session also revealed that there is a willingness from a broad spectrum of stakeholders to engage in policy and regulatory reforms for research, scale up and local empowerment.

Q & A on Monoclonal Antibodies for Malaria Prevention with Ifakara Health Institute’s Dr Said Jongo

Insecticide-treated bed nets (ITNs), indoor residual spraying (IRS) and artemisinin-based combination therapies (ACTs) are the first line tools used for malaria control. The effectiveness of these approaches is fast declining, prompting scientists and other practitioners to explore new malaria intervention tools and strategies. One such tool is the use of monoclonal antibodies to prevent the disease.

In this Q&A, Dr Said Jongo, Consultant Physician and Clinical Epidemiologist at Ifakara Health Institute (IHI) explains how monoclonal antibodies can help support malaria intervention strategies.

What are monoclonal antibodies? 

Monoclonal antibodies are lab-made molecules that mimic the immune system’s ability to fight off harmful pathogens. They are designed to target specific proteins in cells and can block the cell’s function or mark it for destruction. They can be produced in large quantities in vitro and administered by injection or infusion.

Why are monoclonal antibodies now being explored for malaria prevention? 

The development of monoclonal antibodies has revolutionised the treatment of many diseases and holds potential for future therapies. Monoclonal antibodies are used to treat various diseases, including cancer, autoimmune disorders, and infectious diseases like COVID-19. Malaria is caused by a parasite transmitted by mosquitoes, and monoclonal antibodies can target specific proteins (epitopes) on the parasite’s surface, disrupting its ability to infect and replicate in body cells.

Why is this a promising area of research in the fight against malaria?

Monoclonal antibodies are being explored for malaria prevention due to their promising results in clinical trials. Clinical trials have shown that monoclonal antibodies can provide significant protection against malaria infection in humans, even at low doses, and have the potential for long-lasting protection.

What would it take to have countries providing the right environment for monoclonal antibodies research and pharmaceutical production? 

Further research is ongoing to develop effective antibody-based interventions for disease intervention in high-risk populations. For countries to promote research and production of monoclonal antibodies, they need to have regulations in place to ensure that the antibodies are safe and effective. They also need to provide funding and create an environment where scientists have the resources to work on this kind of research. Countries need to have skilled scientists and laboratory facilities to support the research and manufacturing of monoclonal antibodies. Partnerships between different organisations and industries can help create the conditions needed to promote research into monoclonal antibodies. Overall, it will take a collaborative effort between government, industry and academia to promote monoclonal antibody research and production.

What are the current global, regional and national guides on monoclonal antibodies that can support their development and use for malaria prevention? 

Several global, regional, and national organisations have developed guidelines to support the development and use of monoclonal antibodies for malaria prevention. These organisations include the World Health Organization (WHO), the Malaria Vaccine Technology Roadmap, the Roll Back Malaria Partnership, research organisations and academic institutions. These guidelines provide recommendations on the development, testing, and deployment of monoclonal antibodies for malaria, ensuring their safe and effective use. As monoclonal antibodies for malaria prevention is a relatively new and evolving field, the national guidelines in low- and middle-income countries (LMICs) may require significant revisions to address challenges related to their development. The challenges include limited financial resources, inadequate expertise, poor infrastructure, insufficient regulatory controls and, once developed, lack of access to monoclonal antibodies by those that need them the most. These challenges must be addressed to ensure the safe and effective use of monoclonal antibodies for malaria prevention in LMICs.

Do you think monoclonal antibodies will be a game-changer, or should there be caution about their promise? 

Monoclonal antibodies have demonstrated their potential in treating and preventing various diseases, making them a promising technology for malaria prevention and treatment. However, some uncertainties and challenges need to be addressed. One major challenge is the cost of production, distribution, and access to the therapy, which needs to be managed effectively. Additionally, there is the possibility of the malaria parasite developing resistance to monoclonal antibodies, which may limit their efficacy over time. Therefore, it is essential to conduct well-designed clinical trials to assess the safety and efficacy of monoclonal antibodies for malaria prevention and treatment. Finally, to ensure the equitable distribution of monoclonal antibodies, it is crucial to address issues of access, cost, and resistance, particularly in LMICs where the burden of malaria is the highest.